Overview
Navigation through the Investigational New Drug (IND)-enabling activities and acquisition of the full set of resources for this stage of drug development can be challenging for many researchers. To help address these challenges, the National Cancer Institute (NCI) will hold an educational workshop to provide researchers with an interactive setting in which they will gain an understanding of key activities that constitute preclinical product development of anti-cancer agents, to facilitate their successful translation from the bench to the bedside. The workshop will be conducted through ten webinar sessions that are designed to reflect the interrelated, milestone-driven nature of the IND-enabling activities. Furthermore, the program will introduce first-in-human trial design to emphasize a ‘clinical trial-directed' mindset, discuss available NCI translational resources, and share entrepreneurship experience. Lectures will be delivered by subject matter experts from the NCI and the Food and Drug Administration (FDA), as well as from academic and private sectors. Topics and speaker biographies are described in the Agenda and Speaker Bios pages, respectively.
Intended Audience:
Translational scientists from various sectors who are interested in learning more about advancing the development of candidate therapeutics towards the clinic for cancer treatment.
Registration is now open. This workshop is free to attend. Recordings of individual sessions will be posted on the Materials page after the completion of the session.
If you have further questions, please contact chen.weiwei@nih.gov or sharad.verma@nih.gov.